//
sign in
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
Emerging data show benefits of GLP1-RAs and dual GIP/GLP1-RA may extend beyond diabetes & obesity offering improvements in liver disease, neurodegeneration, PCOS, substance use, and more. www.jabfm.org/content/39/1...
1mo
Emerging and Off-Label Uses Of Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) and Dual GIP/GLP1-RAs
Background Glucagon-like peptide-1 receptor agonists (GLP1-RAs) and the glucagon-dependent insulinotropic polypeptide (GIP)/GLP1-RA are approved for type 2 diabetes (T2D) and obesity given their profo...
www.jabfm.org
Journal of the American Board of Family Medicine